{"id":8067,"date":"2024-08-28T17:30:28","date_gmt":"2024-08-28T10:30:28","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=8067"},"modified":"2024-08-28T17:30:28","modified_gmt":"2024-08-28T10:30:28","slug":"harbour-biomed-announces-2024-interim-results","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=8067","title":{"rendered":"Harbour BioMed Announces 2024 Interim Results"},"content":{"rendered":"

CAMBRIDGE, Mass.<\/span>, ROTTERDAM, Netherlands<\/span> and SUZHOU, China<\/span><\/span>, Aug. 28, 2024<\/span><\/span> \/PRNewswire\/ —\u00a0Harbour BioMed (“HBM”, or the “Company”; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology, today announced its interim results for the six months ended June 30, 2024<\/span>.<\/p>\n

\n<\/div>\n

Dr. Jingsong Wang<\/span>, Founder, Chairman and CEO of Harbour BioMed, commented, “In the first half of 2024, Harbour BioMed remained profitable, demonstrating the Company’s remarkable resilience and adaptability in challenging market conditions. Our global operations continue to open new avenues for future growth. Our outstanding performance has validated the feasibility of the Two-Engine strategy, driven by Harbour Therapeutics and Nona Biosciences. We are confident in our ability to enhance value creation and drive sustainable growth by fully unlocking the tremendous potential of our core innovation engine.”<\/p>\n

The Company reported revenues of US$23.7 million<\/span> for the first half of 2024, achieving an overall profit of approximately US$1.4 million<\/span>, with a solid cash balance exceeding US$183 million<\/span>.<\/p>\n

Harbour Therapeutics: Robust Portfolio and Differentiated Pipeline<\/p>\n

The Company has a robust and diversified pipeline with potentially differentiated drug candidates in immuno-oncology and inflammatory and immunology diseases. Key products include HBM9161, HBM4003, HBM9378 and HBM1020.\u00a0The Company aims to deliver at least one IND submission generated from the discovery engine each year.<\/p>\n

Batoclimab (HBM9161) is\u00a0a novel, fully human anti-FcRn (neonatal fragment crystallizable receptor) monoclonal antibody which has the potential to be a breakthrough treatment option for a wide range\u00a0of autoimmune diseases. In June 2023<\/span>, the National Medical Products Administration (NMPA) of China\u00a0accepted the BLA of batoclimab for the treatment of gMG, while in December 2023<\/span>, the Company voluntarily planned to include additional long-term safety data and re-submitted the BLA for batoclimab to the NMPA in June 2024<\/span>, which was shortly accepted in July 2024<\/span>. According to the analysis of the Open-Label extension clinical trial up to November 2023<\/span>, the data demonstrated consistent efficacy and safety of batoclimab in long-term disease management. Its clinical results were published in JAMA Neurology in March 2024<\/span>.<\/p>\n

Batoclimab received the “Breakthrough Therapy Certificate” from the NMPA in 2021 and achieved a positive outcome in the proof-of-concept study for treating Chinese gMG patients in July 2021<\/span>. The positive topline results of its Phase III clinical trial were announced in March 2023<\/span>.<\/p>\n

In October 2022<\/span>, the Company entered into an agreement with NBP Pharma, a wholly owned subsidiary of the CSPC Group, to co-develop batoclimab in Greater China<\/span>. The Company believes that the collaboration with CSPC Group enables the Company to optimize the market potential and advance the clinical development of batoclimab, so as to further maximize the value of batoclimab in Greater China<\/span>.<\/p>\n

Porustobart (HBM4003) is a next-generation,\u00a0fully human anti-CTLA-4 antibody targeting\u00a0cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4). It is the\u00a0first internally developed molecule generated from HCAb Harbour Mice\u00ae platform. Porustobart\u00a0is the first fully human heavy chain only anti CTLA-4 antibody entered into clinical development worldwide, and has favourable properties compared with conventional anti-CTLA-4 antibodies in pre-clinical settings. Notably, porustobart\u00a0exhibits\u00a0unique, favourable properties including significant Treg cell depletion and optimized pharmacokinetics for improved safety. While increasing the potential to selectively deplete intratumoral Treg cells via enhanced antibody-dependent cellular cytotoxicity (ADCC) strategy, the Company\u00a0believes\u00a0porustobart\u00a0will be able to break the significant immune-suppressive barrier of anti-cancer immunotherapies in solid tumors. Porustobart\u00a0has great potential to overcome the efficacy and toxicity bottleneck of the current CTLA-4 therapies, positioning it as\u00a0a key\u00a0product in cancer immunotherapy.<\/p>\n

The Company has implemented a\u00a0global development plan for porustobart across multiple solid tumor types, with adaptive treatment designs. Positive data on\u00a0efficacy and safety have been read out from\u00a0the monotherapy trial targeting advanced solid tumors, as well as the\u00a0trials of combination treatment with PD-1 inhibitor for melanoma, NEN,\u00a0and HCC.\u00a0In January 2024,\u00a0patient enrolment for combination therapy with a PD-1 inhibitor for\u00a0advanced colorectal carcinoma was initiated.<\/p>\n

HBM9378\u00a0is a fully human monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), developed from H2L2 Harbour Mice\u00ae\u00a0platform. It inhibits the TSLP-mediated signalling pathway by blocking the interaction between TSLP and its receptor. TSLP plays important roles in DC cell maturation, T helper 2 (Th2) cell polarization, and inflammation, particularly in both eosinophilic and non-eosinophilic inflammation asthma. HBM9378 features fully human sequences, which reduce the risk of immunogenicity and improve bioavailability compared to other TSLP-targeting competitors. Its optimized long half-life and outstanding biophysical properties provide dosing and formulation benefits.<\/p>\n

HBM9378 has entered the clinical development stage in collaboration with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (Kelun-Biotech). In February 2022<\/span>, HBM9378 received IND approval from the NMPA for the treatment of severe asthma and initiated the Phase I trial in China<\/span>. In October 2023<\/span>, HBM9378 completed the Phase I clinical trial, and the initiation of its Phase II clinical trial is now ongoing. The Company is\u00a0also preparing the IND application for a second indication, chronic obstructive pulmonary disease (COPD), for HBM9378.<\/p>\n

HBM1020\u00a0is a first-in-class, fully human monoclonal antibody generated from Harbour Mice\u00ae platform, targeting B7H7\/HHLA2. As a newly discovered member of the B7 family, B7H7\/HHLA2 expression is found non-overlapping with PD-L1 expression in multiple tumor types, suggesting it may play a key role for tumor cells to escape immune surveillance beyond PD-L1 mechanisms. HBM1020 is the first product targeting B7H7\/HHLA2 in clinical stage globally. With its excellent product design and target features, the Company believes that HBM1020 has significant potential to address unmet medical needs in the treatment of solid tumors, particularly in patients with low PD-L1 expression and those resistant to PD-(L)1 therapies. The Company initiated a Phase I clinical trial in the U.S. in May 2023<\/span> and has since completed multiple dose levels. The latest progress of HBM1020 will be presented at the ESMO Congress 2024.<\/p>\n

Engaged in the discovery and development of differentiated antibody therapeutics in the areas of immuno-oncology and immunology, the Company are also exploring and developing multiple programs, including novel and challenging antibody therapeutics across various disease areas.<\/p>\n

In oncology field, alongside monoclonal antibodies (mAbs) such as HBM1022 (CCR8) and HBM9014 (a LIFR-targeting mAb), the Company is also generating bispecific antibodies from the HBICE\u00ae platform, featuring innovative designs and differentiated mechanisms such as HBM7020 (BCMAxCD3), HBM9027 (PD-L1xCD40), and HBM7004 (B7H4xCD3). In addition, leveraging the advantages of the Harbour Mice\u00ae platform and utilizing the XDC platform, the Company is exploring more therapeutic modalities in oncology, including HBM9033 (a MSLN-targeted ADC) and other ADC\/RDC programs in early stages.<\/p>\n

In the inflammatory and immunology field, the Company has built a robust preclinical pipeline, encompassing bispecific and multi-specific antibody programs in targeting Type 2 pathways and for other inflammatory and immunology conditions.<\/p>\n

Nona Biosciences: An Efficient Value Creation Engine<\/p>\n

As a pioneer in innovative antibody platform technology, the Company continues to empower the innovators in the industry and support its collaborators from I to ITM (Idea to IND) through Nona Biosciences. By leveraging flexible business models and robust internal discovery capabilities, Nona Biosciences is maximizing platform value by combining the strengths of the Company with those of its collaborators. To fully utilize the unique platform technologies, Nona Biosciences continues to explore the expansion of platform technology applications, generating impactful values for the Company. The Company has established partnerships with over 25 industry pioneers and academic researchers, further expanding its collaboration network both in China<\/span> and globally.<\/p>\n

In February 2024<\/span>, Nona Biosciences entered into a collaboration agreement with Boostimmune, a biotech company dedicated to developing next-generation anti-cancer therapies via modulating immune systems. The collaboration aims to leverage Nona Biosciences’ proprietary H2L2 Harbour Mice\u00ae to accelerate the development of ADCs against novel targets.<\/p>\n

In May 2024<\/span>, Nona Biosciences entered into a license agreement with Astra Zeneca for preclinical monoclonal antibodies that will be used to create targeted therapies in oncology. Under the terms of the agreement, Nona Biosciences shall receive US$19 million<\/span> upon completion of the transaction, is eligible to receive an additional US$10 million<\/span> in potential near-term milestone payments and up to US$575 million<\/span> upon achieving specified development, regulatory, and commercial milestones, as well as tiered royalty payments on net sales. In addition, Nona Biosciences is eligible to receive payments for the option programs should Astra Zeneca exercise these options.<\/p>\n

In July 2024<\/span>, Nona Biosciences entered into a collaboration agreement with Alaya.bio,\u00a0a biotechnology company developing a novel polymeric delivery platform, to precisely target and reprogram cells\u00a0in situ\u00a0and thus to significantly simplify the way CAR-T cell therapies are being developed, manufactured and administered.<\/p>\n

Nona Biosciences continuous to optimize, upgrade and further develop its technology, establishing a robust antibody discovery platform, protein engineering platform, conjugation technology platform, HCAb-CAR screening platform and delivery technology platform to use mRNA-encoding target gene as immunogen to tackle difficult targets. These platforms enable the Company to address more novel and challenging drug targets globally.<\/p>\n

About Harbour BioMed <\/p>\n

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on immunology and oncology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners, and select acquisitions.<\/p>\n

The proprietary antibody technology platforms Harbour Mice\u00ae\u00a0generates fully human monoclonal antibodies in two heavy and two light chains (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE\u00ae) bispecific antibody technology is capable of delivering tumor-killing effects unachievable by traditional combination therapies. Integrating Harbour Mice\u00ae, and HBICE\u00ae with a single B cell cloning platform, our antibody discovery engine is highly unique and efficient for the development of next-generation therapeutic antibodies. For further information, please visit www.harbourbiomed.com<\/a> \u00a0<\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n

CAMBRIDGE, Mass.<\/span>, ROTTERDAM, Netherlands<\/span> and SUZHOU, China<\/span><\/span>, Aug. 28, 2024<\/span><\/span> \/PRNewswire\/ —\u00a0Harbour BioMed (“HBM”, or the “Company”; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology, today announced its interim results for the six months ended June 30, 2024<\/span>.<\/p>\n

\n<\/div>\n

Dr. Jingsong Wang<\/span>, Founder, Chairman and CEO of Harbour BioMed, commented, “In the first half of 2024, Harbour BioMed remained profitable, demonstrating the Company’s remarkable resilience and adaptability in challenging market conditions. Our global operations continue to open new avenues for future growth. Our outstanding performance has validated the feasibility of the Two-Engine strategy, driven by Harbour Therapeutics and Nona Biosciences. We are confident in our ability to enhance value creation and drive sustainable growth by fully unlocking the tremendous potential of our core innovation engine.”<\/p>\n

The Company reported revenues of US$23.7 million<\/span> for the first half of 2024, achieving an overall profit of approximately US$1.4 million<\/span>, with a solid cash balance exceeding US$183 million<\/span>.<\/p>\n

Harbour Therapeutics: Robust Portfolio and Differentiated Pipeline<\/p>\n

The Company has a robust and diversified pipeline with potentially differentiated drug candidates in immuno-oncology and inflammatory and immunology diseases. Key products include HBM9161, HBM4003, HBM9378 and HBM1020.\u00a0The Company aims to deliver at least one IND submission generated from the discovery engine each year.<\/p>\n

Batoclimab (HBM9161) is\u00a0a novel, fully human anti-FcRn (neonatal fragment crystallizable receptor) monoclonal antibody which has the potential to be a breakthrough treatment option for a wide range\u00a0of autoimmune diseases. In June 2023<\/span>, the National Medical Products Administration (NMPA) of China\u00a0accepted the BLA of batoclimab for the treatment of gMG, while in December 2023<\/span>, the Company voluntarily planned to include additional long-term safety data and re-submitted the BLA for batoclimab to the NMPA in June 2024<\/span>, which was shortly accepted in July 2024<\/span>. According to the analysis of the Open-Label extension clinical trial up to November 2023<\/span>, the data demonstrated consistent efficacy and safety of batoclimab in long-term disease management. Its clinical results were published in JAMA Neurology in March 2024<\/span>.<\/p>\n

Batoclimab received the “Breakthrough Therapy Certificate” from the NMPA in 2021 and achieved a positive outcome in the proof-of-concept study for treating Chinese gMG patients in July 2021<\/span>. The positive topline results of its Phase III clinical trial were announced in March 2023<\/span>.<\/p>\n

In October 2022<\/span>, the Company entered into an agreement with NBP Pharma, a wholly owned subsidiary of the CSPC Group, to co-develop batoclimab in Greater China<\/span>. The Company believes that the collaboration with CSPC Group enables the Company to optimize the market potential and advance the clinical development of batoclimab, so as to further maximize the value of batoclimab in Greater China<\/span>.<\/p>\n

Porustobart (HBM4003) is a next-generation,\u00a0fully human anti-CTLA-4 antibody targeting\u00a0cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4). It is the\u00a0first internally developed molecule generated from HCAb Harbour Mice\u00ae platform. Porustobart\u00a0is the first fully human heavy chain only anti CTLA-4 antibody entered into clinical development worldwide, and has favourable properties compared with conventional anti-CTLA-4 antibodies in pre-clinical settings. Notably, porustobart\u00a0exhibits\u00a0unique, favourable properties including significant Treg cell depletion and optimized pharmacokinetics for improved safety. While increasing the potential to selectively deplete intratumoral Treg cells via enhanced antibody-dependent cellular cytotoxicity (ADCC) strategy, the Company\u00a0believes\u00a0porustobart\u00a0will be able to break the significant immune-suppressive barrier of anti-cancer immunotherapies in solid tumors. Porustobart\u00a0has great potential to overcome the efficacy and toxicity bottleneck of the current CTLA-4 therapies, positioning it as\u00a0a key\u00a0product in cancer immunotherapy.<\/p>\n

The Company has implemented a\u00a0global development plan for porustobart across multiple solid tumor types, with adaptive treatment designs. Positive data on\u00a0efficacy and safety have been read out from\u00a0the monotherapy trial targeting advanced solid tumors, as well as the\u00a0trials of combination treatment with PD-1 inhibitor for melanoma, NEN,\u00a0and HCC.\u00a0In January 2024,\u00a0patient enrolment for combination therapy with a PD-1 inhibitor for\u00a0advanced colorectal carcinoma was initiated.<\/p>\n

HBM9378\u00a0is a fully human monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), developed from H2L2 Harbour Mice\u00ae\u00a0platform. It inhibits the TSLP-mediated signalling pathway by blocking the interaction between TSLP and its receptor. TSLP plays important roles in DC cell maturation, T helper 2 (Th2) cell polarization, and inflammation, particularly in both eosinophilic and non-eosinophilic inflammation asthma. HBM9378 features fully human sequences, which reduce the risk of immunogenicity and improve bioavailability compared to other TSLP-targeting competitors. Its optimized long half-life and outstanding biophysical properties provide dosing and formulation benefits.<\/p>\n

HBM9378 has entered the clinical development stage in collaboration with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (Kelun-Biotech). In February 2022<\/span>, HBM9378 received IND approval from the NMPA for the treatment of severe asthma and initiated the Phase I trial in China<\/span>. In October 2023<\/span>, HBM9378 completed the Phase I clinical trial, and the initiation of its Phase II clinical trial is now ongoing. The Company is\u00a0also preparing the IND application for a second indication, chronic obstructive pulmonary disease (COPD), for HBM9378.<\/p>\n

HBM1020\u00a0is a first-in-class, fully human monoclonal antibody generated from Harbour Mice\u00ae platform, targeting B7H7\/HHLA2. As a newly discovered member of the B7 family, B7H7\/HHLA2 expression is found non-overlapping with PD-L1 expression in multiple tumor types, suggesting it may play a key role for tumor cells to escape immune surveillance beyond PD-L1 mechanisms. HBM1020 is the first product targeting B7H7\/HHLA2 in clinical stage globally. With its excellent product design and target features, the Company believes that HBM1020 has significant potential to address unmet medical needs in the treatment of solid tumors, particularly in patients with low PD-L1 expression and those resistant to PD-(L)1 therapies. The Company initiated a Phase I clinical trial in the U.S. in May 2023<\/span> and has since completed multiple dose levels. The latest progress of HBM1020 will be presented at the ESMO Congress 2024.<\/p>\n

Engaged in the discovery and development of differentiated antibody therapeutics in the areas of immuno-oncology and immunology, the Company are also exploring and developing multiple programs, including novel and challenging antibody therapeutics across various disease areas.<\/p>\n

In oncology field, alongside monoclonal antibodies (mAbs) such as HBM1022 (CCR8) and HBM9014 (a LIFR-targeting mAb), the Company is also generating bispecific antibodies from the HBICE\u00ae platform, featuring innovative designs and differentiated mechanisms such as HBM7020 (BCMAxCD3), HBM9027 (PD-L1xCD40), and HBM7004 (B7H4xCD3). In addition, leveraging the advantages of the Harbour Mice\u00ae platform and utilizing the XDC platform, the Company is exploring more therapeutic modalities in oncology, including HBM9033 (a MSLN-targeted ADC) and other ADC\/RDC programs in early stages.<\/p>\n

In the inflammatory and immunology field, the Company has built a robust preclinical pipeline, encompassing bispecific and multi-specific antibody programs in targeting Type 2 pathways and for other inflammatory and immunology conditions.<\/p>\n

Nona Biosciences: An Efficient Value Creation Engine<\/p>\n

As a pioneer in innovative antibody platform technology, the Company continues to empower the innovators in the industry and support its collaborators from I to ITM (Idea to IND) through Nona Biosciences. By leveraging flexible business models and robust internal discovery capabilities, Nona Biosciences is maximizing platform value by combining the strengths of the Company with those of its collaborators. To fully utilize the unique platform technologies, Nona Biosciences continues to explore the expansion of platform technology applications, generating impactful values for the Company. The Company has established partnerships with over 25 industry pioneers and academic researchers, further expanding its collaboration network both in China<\/span> and globally.<\/p>\n

In February 2024<\/span>, Nona Biosciences entered into a collaboration agreement with Boostimmune, a biotech company dedicated to developing next-generation anti-cancer therapies via modulating immune systems. The collaboration aims to leverage Nona Biosciences’ proprietary H2L2 Harbour Mice\u00ae to accelerate the development of ADCs against novel targets.<\/p>\n

In May 2024<\/span>, Nona Biosciences entered into a license agreement with Astra Zeneca for preclinical monoclonal antibodies that will be used to create targeted therapies in oncology. Under the terms of the agreement, Nona Biosciences shall receive US$19 million<\/span> upon completion of the transaction, is eligible to receive an additional US$10 million<\/span> in potential near-term milestone payments and up to US$575 million<\/span> upon achieving specified development, regulatory, and commercial milestones, as well as tiered royalty payments on net sales. In addition, Nona Biosciences is eligible to receive payments for the option programs should Astra Zeneca exercise these options.<\/p>\n

In July 2024<\/span>, Nona Biosciences entered into a collaboration agreement with Alaya.bio,\u00a0a biotechnology company developing a novel polymeric delivery platform, to precisely target and reprogram cells\u00a0in situ\u00a0and thus to significantly simplify the way CAR-T cell therapies are being developed, manufactured and administered.<\/p>\n

Nona Biosciences continuous to optimize, upgrade and further develop its technology, establishing a robust antibody discovery platform, protein engineering platform, conjugation technology platform, HCAb-CAR screening platform and delivery technology platform to use mRNA-encoding target gene as immunogen to tackle difficult targets. These platforms enable the Company to address more novel and challenging drug targets globally.<\/p>\n

About Harbour BioMed <\/p>\n

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on immunology and oncology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners, and select acquisitions.<\/p>\n

The proprietary antibody technology platforms Harbour Mice\u00ae\u00a0generates fully human monoclonal antibodies in two heavy and two light chains (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE\u00ae) bispecific antibody technology is capable of delivering tumor-killing effects unachievable by traditional combination therapies. Integrating Harbour Mice\u00ae, and HBICE\u00ae with a single B cell cloning platform, our antibody discovery engine is highly unique and efficient for the development of next-generation therapeutic antibodies. For further information, please visit www.harbourbiomed.com<\/a> \u00a0<\/p>\n

<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-8067","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/8067","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=8067"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/8067\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=8067"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=8067"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=8067"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}